Risk factor
Considerable default risk
Profitability factor
Good growth
About
Hanmi Science Co., Ltd. operates through its subsidiaries to produce and distribute pharmaceutical products both within South Korea and internationally. The company's research and development initiatives primarily target treatments for diabetes and various types of cancer. Its extensive product line further includes active pharmaceutical ingredients, general therapeutic drugs, nutritional supplements, and a variety of health-related goods and services. Additionally, it manages an online pharmacy platform and provides automated systems for pharmaceutical administration. The firm, which was initially established as Hanmi Holdings Co., Ltd. in 1973, adopted its current name, Hanmi Science Co., Ltd., in March 2012, and its corporate headquarters are situated in Seoul, South Korea.
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. Specifically, the stock is fairly valued on P/E, overvalued on EV/